

Antonio Daniele

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7966866/publications.pdf>

Version: 2024-02-01

48
papers

4,778
citations

218677

26
h-index

206112

48
g-index

50
all docs

50
docs citations

50
times ranked

8613
citing authors

#	ARTICLE	IF	CITATIONS
1	Processed meat consumption and the risk of incident late-onset depression: a 12-year follow-up of the Salus in Apulia Study. <i>Age and Ageing</i> , 2022, 51, .	1.6	5
2	The diagnostic accuracy of late-life depression is influenced by subjective memory complaints and educational level in an older population in Southern Italy. <i>Psychiatry Research</i> , 2022, 308, 114346.	3.3	3
3	Frailty and outcome after traumatic brain injury. <i>Lancet Neurology</i> , The, 2022, 21, 107-108.	10.2	6
4	ALZT-OP1: an experimental combination regimen for the treatment of Alzheimerâ€™s disease. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 759-771.	4.1	6
5	Oral frailty and neurodegeneration in Alzheimerâ€™s disease. <i>Neural Regeneration Research</i> , 2021, 16, 2149.	3.0	34
6	Vitamin D in the development and progression of alzheimerâ€™s disease: implications for clinical management. <i>Expert Review of Neurotherapeutics</i> , 2021, 21, 287-301.	2.8	9
7	Physical Frailty, Multimorbidity, and All-Cause Mortality in an Older Population From Southern Italy: Results from the Salus in Apulia Study. <i>Journal of the American Medical Directors Association</i> , 2021, 22, 598-605.	2.5	53
8	Suicidal behaviour in older age: A systematic review of risk factors associated to suicide attempts and completed suicides. <i>Neuroscience and Biobehavioral Reviews</i> , 2021, 127, 193-211.	6.1	54
9	Anti-amyloid-Î² protein agents for the treatment of Alzheimerâ€™s disease: an update on emerging drugs. <i>Expert Opinion on Emerging Drugs</i> , 2020, 25, 319-335.	2.4	57
10	The relationship between epigenetics and microbiota in neuropsychiatric diseases. <i>Epigenomics</i> , 2020, 12, 1559-1568.	2.1	11
11	Social Frailty in the COVID-19 Pandemic Era. <i>Frontiers in Psychiatry</i> , 2020, 11, 577113.	2.6	20
12	Can pharmacotherapy effectively reduce Alzheimerâ€™s related agitation?. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 1517-1522.	1.8	4
13	Development of disease-modifying drugs for frontotemporal dementia spectrum disorders. <i>Nature Reviews Neurology</i> , 2020, 16, 213-228.	10.1	73
14	The Challenge of Antidepressant Therapeutics in Alzheimerâ€™s Disease. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1260, 267-281.	1.6	4
15	Biopsychosocial frailty and the risk of incident dementia: The Italian longitudinal study on aging. <i>Alzheimer's and Dementia</i> , 2019, 15, 1019-1028.	0.8	47
16	Pharmacogenetics in the clinical analysis laboratory: clinical practice, research, and drug development pipeline. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2019, 15, 751-765.	3.3	0
17	Promising therapies for the treatment of frontotemporal dementia clinical phenotypes: from symptomatic to disease-modifying drugs. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 1091-1107.	1.8	15
18	Disease-modifying therapies for tauopathies: agents in the pipeline. <i>Expert Review of Neurotherapeutics</i> , 2019, 19, 397-408.	2.8	15

#	ARTICLE	IF	CITATIONS
19	The Role of Biomarkers in Psychiatry. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1118, 135-162.	1.6	29
20	Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates A β , tau, immunity and lipid processing. <i>Nature Genetics</i> , 2019, 51, 414-430.	21.4	1,962
21	Are antibodies directed against amyloid- β (A β) oligomers the last call for the A β hypothesis of Alzheimer's disease?. <i>Immunotherapy</i> , 2019, 11, 3-6.	2.0	50
22	Sensorial frailty: age-related hearing loss and the risk of cognitive impairment and dementia in later life. <i>Therapeutic Advances in Chronic Disease</i> , 2019, 10, 204062231881100.	2.5	68
23	Botulinum Toxin Type A for the Treatment of Lower Limb Spasticity after Stroke. <i>Drugs</i> , 2019, 79, 143-160.	10.9	38
24	Role of CLU, PICALM, and TNK1 Genotypes in Aging With and Without Alzheimer's Disease. <i>Molecular Neurobiology</i> , 2018, 55, 4333-4344.	4.0	19
25	Executive Dysfunction Detected with the Frontal Assessment Battery in Alzheimer's Disease Versus Vascular Dementia. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 699-711.	2.6	17
26	Different Cognitive Frailty Models and Health- and Cognitive-related Outcomes in Older Age: From Epidemiology to Prevention. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 993-1012.	2.6	214
27	Pharmacotherapy for the treatment of depression in patients with Alzheimer's disease: a treatment-resistant depressive disorder. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 823-842.	1.8	43
28	An Old Challenge with New Promises: A Systematic Review on Comprehensive Geriatric Assessment in Long-Term Care Facilities. <i>Rejuvenation Research</i> , 2018, 21, 3-14.	1.8	25
29	The potential of solanezumab and gantenerumab to prevent Alzheimer's disease in people with inherited mutations that cause its early onset. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 25-35.	3.1	34
30	BACE inhibitors in clinical development for the treatment of Alzheimer's disease. <i>Expert Review of Neurotherapeutics</i> , 2018, 18, 847-857.	2.8	66
31	Nutritional interventions and cognitive-related outcomes in patients with late-life cognitive disorders: A systematic review. <i>Neuroscience and Biobehavioral Reviews</i> , 2018, 95, 480-498.	6.1	27
32	Nutritional Intervention as a Preventive Approach for Cognitive-Related Outcomes in Cognitively Healthy Older Adults: A Systematic Review. <i>Journal of Alzheimer's Disease</i> , 2018, 64, S229-S254.	2.6	38
33	Reversible Cognitive Frailty, Dementia, and All-Cause Mortality. The Italian Longitudinal Study on Aging. <i>Journal of the American Medical Directors Association</i> , 2017, 18, 89.e1-89.e8.	2.5	126
34	Relationships of Dietary Patterns, Foods, and Micro- and Macronutrients with Alzheimer's Disease and Late-Life Cognitive Disorders: A Systematic Review. <i>Journal of Alzheimer's Disease</i> , 2017, 59, 815-849.	2.6	249
35	Psychotropic drugs and CYP2D6 in late-life psychiatric and neurological disorders. What do we know?. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 1373-1385.	2.4	8
36	Cognitive frailty: a potential target for secondary prevention of dementia. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017, 13, 1023-1027.	3.3	40

#	ARTICLE	IF	CITATIONS
37	Innovative biomarkers in psychiatric disorders: a major clinical challenge in psychiatry. Expert Review of Proteomics, 2017, 14, 809-824.	3.0	36
38	Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Nature Genetics, 2017, 49, 1373-1384.	21.4	783
39	Additive Role of a Potentially Reversible Cognitive Frailty Model and Inflammatory State on the Risk of Disability: The Italian Longitudinal Study on Aging. American Journal of Geriatric Psychiatry, 2017, 25, 1236-1248.	1.2	90
40	Pharmacogenetics of neurological and psychiatric diseases at older age: has the time come?. Expert Opinion on Drug Metabolism and Toxicology, 2017, 13, 259-277.	3.3	13
41	Tau-Centric Targets and Drugs in Clinical Development for the Treatment of Alzheimer's Disease. BioMed Research International, 2016, 2016, 1-15.	1.9	138
42	Psychiatry meets pharmacogenetics for the treatment of revolving door patients with psychiatric disorders. Expert Review of Neurotherapeutics, 2016, 16, 1357-1369.	2.8	10
43	Emerging drugs to reduce abnormal β -amyloid protein in Alzheimer's disease patients. Expert Opinion on Emerging Drugs, 2016, 21, 377-391.	2.4	54
44	Tau-based therapeutics for Alzheimer's disease: active and passive immunotherapy. Immunotherapy, 2016, 8, 1119-1134.	2.0	61
45	The pharmacogenetic road to avoid adverse drug reactions and therapeutic failures in revolving door patients with psychiatric illnesses: focus on the CYP2D6 isoenzymes. Expert Review of Precision Medicine and Drug Development, 2016, 1, 431-442.	0.7	6
46	High doses of incobotulinumtoxinA for the treatment of post-stroke spasticity: are they safe and effective?. Expert Opinion on Drug Metabolism and Toxicology, 2016, 12, 843-846.	3.3	10
47	Tau-directed approaches for the treatment of Alzheimer's disease: focus on leuco-methylthioninium. Expert Review of Neurotherapeutics, 2016, 16, 259-277.	2.8	35
48	Freezing of gait in Parkinson's disease: The paradoxical interplay between gait and cognition. Parkinsonism and Related Disorders, 2014, 20, 824-829.	2.2	24